714 related articles for article (PubMed ID: 33242394)
1. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.
Liu H; Wu NC; Yuan M; Bangaru S; Torres JL; Caniels TG; van Schooten J; Zhu X; Lee CD; Brouwer PJM; van Gils MJ; Sanders RW; Ward AB; Wilson IA
Immunity; 2020 Dec; 53(6):1272-1280.e5. PubMed ID: 33242394
[TBL] [Abstract][Full Text] [Related]
2. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity.
Liu H; Wu NC; Yuan M; Bangaru S; Torres JL; Caniels TG; van Schooten J; Zhu X; Lee CD; Brouwer PJM; van Gils MJ; Sanders RW; Ward AB; Wilson IA
bioRxiv; 2020 Aug; ():. PubMed ID: 32793906
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
5. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
[TBL] [Abstract][Full Text] [Related]
6. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.
Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH
MAbs; 2022; 14(1):2021601. PubMed ID: 35030983
[TBL] [Abstract][Full Text] [Related]
7. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
8. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Zhou D; Duyvesteyn HME; Chen CP; Huang CG; Chen TH; Shih SR; Lin YC; Cheng CY; Cheng SH; Huang YC; Lin TY; Ma C; Huo J; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Donat RF; Godwin K; Buttigieg KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll MW; Gilbert-Jaramillo J; Knight ML; James W; Owens RJ; Naismith JH; Townsend AR; Fry EE; Zhao Y; Ren J; Stuart DI; Huang KA
Nat Struct Mol Biol; 2020 Oct; 27(10):950-958. PubMed ID: 32737466
[TBL] [Abstract][Full Text] [Related]
10. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.
Jiang M; Zhang G; Liu H; Ding P; Liu Y; Tian Y; Wang Y; Wang A
Front Immunol; 2021; 12():707977. PubMed ID: 34621266
[TBL] [Abstract][Full Text] [Related]
11. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
12. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
Rappazzo CG; Tse LV; Kaku CI; Wrapp D; Sakharkar M; Huang D; Deveau LM; Yockachonis TJ; Herbert AS; Battles MB; O'Brien CM; Brown ME; Geoghegan JC; Belk J; Peng L; Yang L; Hou Y; Scobey TD; Burton DR; Nemazee D; Dye JM; Voss JE; Gunn BM; McLellan JS; Baric RS; Gralinski LE; Walker LM
Science; 2021 Feb; 371(6531):823-829. PubMed ID: 33495307
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.
Lv Z; Deng YQ; Ye Q; Cao L; Sun CY; Fan C; Huang W; Sun S; Sun Y; Zhu L; Chen Q; Wang N; Nie J; Cui Z; Zhu D; Shaw N; Li XF; Li Q; Xie L; Wang Y; Rao Z; Qin CF; Wang X
Science; 2020 Sep; 369(6510):1505-1509. PubMed ID: 32703908
[TBL] [Abstract][Full Text] [Related]
14. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
Liu H; Yuan M; Huang D; Bangaru S; Zhao F; Lee CD; Peng L; Barman S; Zhu X; Nemazee D; Burton DR; van Gils MJ; Sanders RW; Kornau HC; Reincke SM; Prüss H; Kreye J; Wu NC; Ward AB; Wilson IA
Cell Host Microbe; 2021 May; 29(5):806-818.e6. PubMed ID: 33894127
[TBL] [Abstract][Full Text] [Related]
15. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
[TBL] [Abstract][Full Text] [Related]
16. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
[TBL] [Abstract][Full Text] [Related]
17. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.
Park YJ; De Marco A; Starr TN; Liu Z; Pinto D; Walls AC; Zatta F; Zepeda SK; Bowen JE; Sprouse KR; Joshi A; Giurdanella M; Guarino B; Noack J; Abdelnabi R; Foo SC; Rosen LE; Lempp FA; Benigni F; Snell G; Neyts J; Whelan SPJ; Virgin HW; Bloom JD; Corti D; Pizzuto MS; Veesler D
Science; 2022 Jan; 375(6579):449-454. PubMed ID: 34990214
[TBL] [Abstract][Full Text] [Related]
19. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
20. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
